Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460903 | 0.92 | BRAF (0.79) | BRAFERN1 | |
| SCHEMBL14642968 | 0.90 | BRAF (0.76) | BRAFERN1 | |
| SCHEMBL14574688 | 0.90 | BRAF (0.65) | BRAFERN1 | |
| SCHEMBL1462158 | 0.88 | BRAF (1.00) | BRAFERN1 | |
| SCHEMBL12825883 | 0.87 | BRAF (0.79) | BRAFERN1 | |
| SCHEMBL1461023 | 0.86 | BRAF (0.70) | BRAFERN1 | |
| SCHEMBL12826161 | 0.85 | BRAF (0.62) | BRAFERN1 | |
| SCHEMBL14574799 | 0.84 | BRAF (0.58) | BRAFERN1 | |
| SCHEMBL12826163 | 0.84 | BRAF (0.58) | BRAFERN1 | |
| SCHEMBL1461893 | 0.84 | BRAF (0.80) | BRAFERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885ERN1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.